Related Experiment Video
Updated: Oct 14, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches
Saad Al Zamane1, Fahim Alam Nobel2, Ruksana Akter Jebin2
1Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail, 1902, Bangladesh.
Abstract:
The coronavirus family has been infecting the human population for the past two decades, but the ongoing coronavirus called SARS-CoV-2 has posed an enigmatic challenge to global public health security. Since last year, the mutagenic quality of this virus is causing changes to its genetic material. To prevent those situations, the FDA approved some emergency vaccines but there is no assurance that these will function properly in the complex human body system. In point of view, a short but efficient effort has made in this study to develop an immune epitope-based therapy for the rapid exploitation of SARS-CoV-2 by applying in silico structural biology and advancing immune information strategies. The antigenic epitopes were screened from the Surface, Membrane, Envelope proteins of SARS-CoV-2 and passed through several immunological filters to determine the best possible one. According to this, 7CD4+, 10CD8+ and 5 B-cell epitopes were found to be prominent, antigenic, immunogenic, and most importantly, highly conserved among 128 Bangladeshi and 110 other infected countries SARS-CoV-2 variants. After that, the selected epitopes and adjuvant were linked to finalize the multi-epitope vaccine by appropriate linkers. The immune simulation disclosed that the engineered vaccine could activate both humoral and innate immune responses. For the prediction of an effective binding, molecular docking was carried out between the vaccine and immunological receptors (TLRs). Strong binding affinity and good docking scores clarified the stringency of the vaccines. Furthermore, MD simulation was performed within the highest binding affinity complex to observe the stability. Codon optimization and other physicochemical properties revealed that the vaccine would be suitable for a higher expression at cloning level. So, monitoring the overall in silico assessment, we anticipated that our engineered vaccine would be a plausible prevention against COVID-19.
Insights
This study developed a novel multi-epitope vaccine for COVID-19 using in silico methods. The engineered vaccine demonstrated potential for activating immune responses and ensuring stability against SARS-CoV-2 variants.
Area of Science:
- * Computational immunology and structural biology
- * Infectious disease research and vaccine development
Background:
- * Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) poses a significant global health threat due to its rapid mutation rate.
- * Existing emergency vaccines for COVID-19 lack guaranteed efficacy in diverse human physiological conditions.
- * The need for robust and adaptable vaccine strategies against evolving SARS-CoV-2 strains is critical.
Purpose of the Study:
- * To design and computationally evaluate an effective immune epitope-based vaccine against SARS-CoV-2.
- * To identify conserved antigenic epitopes for a multi-epitope vaccine targeting global SARS-CoV-2 variants.
- * To predict the vaccine's immunogenicity, stability, and potential for high expression.
Main Methods:
- * In silico screening of Surface, Membrane, and Envelope proteins for antigenic epitopes.
- * Immunological filtering, molecular docking with Toll-like Receptors (TLRs), and Molecular Dynamics (MD) simulations.
- * Codon optimization and assessment of physicochemical properties for vaccine expression.
Main Results:
- * Identification of 7 CD4+, 10 CD8+, and 5 B-cell epitopes highly conserved across 128 Bangladeshi and 110 international SARS-CoV-2 variants.
- * Immune simulations indicated the engineered vaccine activates both humoral and innate immune responses.
- * Molecular docking and MD simulations confirmed strong binding affinity and stability of the vaccine construct with TLRs.
Conclusions:
- * The in silico developed multi-epitope vaccine shows promise as a potential preventative measure against COVID-19.
- * The vaccine's design ensures high conservation across diverse SARS-CoV-2 strains, addressing mutational challenges.
- * Computational assessments suggest suitability for high expression, facilitating further development and application.
